AMPH Amphastar Pharmaceuticals, Inc.
Healthcare$18.81+2.17%ClosedMarket Cap: $829.4M
As of 2026-05-26
Valuation
P/E (TTM)
9.54
PEG
—
P/B
1.08
P/S
1.13
EV/EBITDA
8.51
DCF Value
$83.49
FCF Yield
16.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
47.3%
Operating Margin
16.2%
Net Margin
11.0%
ROE
10.2%
ROA
4.8%
ROIC
6.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $171.2M | 41.1% | $13.6M | $6.4M | $— | — |
| Q4 null | $183.1M | 46.8% | $35.6M | $24.4M | $— | — |
| FY null | $719.9M | 49.5% | $140.4M | $98.1M | $— | — |
| Q3 null | $191.8M | 51.4% | $25.3M | $17.4M | $— | — |
| Q2 null | $174.4M | 49.6% | $42.2M | $31.0M | $— | — |
| Q1 null | $170.5M | 50.0% | $37.3M | $25.3M | $— | — |
| Q4 null | $186.5M | 46.5% | $45.1M | $38.0M | $— | — |
| FY null | $732.0M | 51.1% | $205.4M | $159.5M | $— | — |
| Q3 null | $188.8M | 54.0% | $57.0M | $40.4M | $— | — |
| Q2 null | $182.4M | 52.2% | $55.2M | $37.9M | $— | — |
| Q1 null | $171.8M | 50.8% | $48.0M | $43.2M | $— | — |
| Q4 2023 | $178.1M | 54.0% | $54.0M | $36.2M | $0.68 | — |